NCT06022822 2026-03-18
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
13 trialsNCT06654336 2026-03-13
RATIONAL
Ontario Clinical Oncology Group (OCOG)
Phase 2 Recruiting
NCT04288687 2026-03-04
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT06798558 2026-02-19
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Hackensack Meridian Health
Phase 2 Recruiting
NCT04175431 2025-12-18
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
University of Washington
Phase 2 Recruiting
NCT06499870 2025-10-21
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT03361735 2025-05-02
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03654638 2025-04-04
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT03762759 2024-05-17
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Emory University
Phase 2 Active not recruiting
NCT02721979 2023-02-09
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
University of Washington
Phase 2 Terminated
NCT04020094 2021-09-22
AtezoVax
University of Utah
Phase 2 Withdrawn
NCT02168062 2020-07-23
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT00183924 2014-05-22
Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.
University of Southern California
Phase 2 Completed